William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sami Corwin has given his Buy rating due to a combination of factors that highlight uniQure’s promising advancements in treating Huntington’s disease. The company announced positive results from its Phase I/II study of AMT-130, demonstrating a significant 75% reduction in disease progression for patients receiving the high-dose treatment. This outcome was measured using the composite Unified Huntington’s Disease Rating Scale (cUHDRS), indicating a strong therapeutic effect.
Additionally, uniQure’s financial position was bolstered by securing a $175 million nondilutive senior secured term loan facility, providing the company with the necessary capital to advance its clinical programs. The study also showed favorable trends in secondary cognitive and motor measures, with a notable 60% slowing of progression on the Total Functional Capacity (TFC) scale, which is crucial for assessing patients’ ability to live independently. These results, combined with the company’s strategic financial moves, underpin Corwin’s confidence in uniQure’s future prospects and justify the Buy rating.
In another report released today, RBC Capital also assigned a Buy rating to the stock with a $55.00 price target.